Cloud Pharmaceuticals Announces Partnering Sessions and Presentation Schedule

RESEARCH TRIANGLE PARK, N.C., Sept. 19, 2014 /PRNewswire/ -- For Cloud Pharmaceuticals, Inc., a therapeutics company focused on cloud-based drug design and development, partnering is an integral part of its business strategy. The company's mission is to design new drugs and identify early stage, preclinical, IND, and Phase 1 and 2 partners to further their development. The company also partners with funds to enhance its portfolio investments. To support this business model, Cloud Pharmaceuticals will be participating in the following industry and investor events:

• BioPharm America
  September 22 – 24, 2014
  Boston, MS

Cloud Pharmaceuticals will participate in partnering sessions at BioPharm America, which helps foster biotech industry partnerships by enabling face-to-face meetings between biotech and pharma executives from around the world to help them identify and enter strategic relationships.

• BIO Investor Forum
  October 7 – 8, 2014
  San Francisco, CA

Cloud Pharmaceuticals will participate in partnering sessions at the BIO Investor Forum, an international biotech investor conference focused on early and established private companies as well as emerging public companies.

• Life Sciences Summit
  October 28, 2014
  New York, NY

Cloud Pharmaceuticals' CEO Ed Addison will be a featured speaker as well as attend partnering sessions at The Life Sciences Summit, an early stage investor and business development conference that highlights innovation.

• Southeast BIO (SEBIO) Investor & Partnering Forum
  November 11 – 13, 2014
  Atlanta, GA

Cloud Pharmaceuticals' CEO Ed Addison will be a featured speaker as well as attend partnering sessions at the Southeast BIO (SEBIO) Investor & Partnering Forum. SEBIO enables companies to meet key decision makers in the regional and national life science and medical technology communities.

• In Silico Drug Discovery Conference
  December 3 – 4, 2014
  Research Triangle Park, NC

Cloud Pharmaceuticals' CEO Ed Addison will moderate a panel on in silico drug discovery as well as attend partnering sessions at the In Silico Drug Discovery Conference. The conference combines the best of cutting-edge industry approaches with recent academic research for in silico drug discovery.

To learn more please visit www.cloudpharmaceuticals.com and see the contact information to schedule a meeting with a representative from Cloud Pharmaceuticals.

About Cloud Pharmaceuticals, Inc.

Cloud Pharmaceuticals is a leader in the computational design of new drugs and subsequent rapid, information-driven drug development. We accelerate the drug discovery and design process in a way that delivers tangible results and true value for our partners. For information visit www.cloudpharmaceuticals.com.

SOURCE Cloud Pharmaceuticals, Inc.